Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 768

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 768
---
 class A ordinary shares subject to possible redemption |     | $                                          |  124,162 |   |     | $                                          |  803,885 |   |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. F-37

#### Denali Capital Acquisition Corp.

### Notes to Unaudited Consolidated Financial Statements
NOTE 1 – ORGANIZATION AND BUSINESS OPERATION Denali Capital Acquisition Corp. (the “Company” or “Denali”) is a newly organized blank check company incorporated in the Cayman Islands on January 5, 2022. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses (a “Business Combination”). As of March 31, 2025, the Company had not commenced any operations. All activity for the period from January 5, 2022 (inception) through March 31, 2025, relates to the Company’s organizational activities, those necessary to prepare for and complete the initial public offering (“IPO”), identifying a target company for a business combination, and activities in connection with an initial business combination, including with respect to our proposed business combination with Semnur Pharmaceuticals, Inc (“Semnur”). The Company does not expect to generate any operating revenues until after the completion of an initial Business Combination. The Company is generating non-operatingincome in the form of income from the investment of proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end. The Company’s sponsor is Denali Capital Global Investments LLC, a Cayman Islands limited liability company (the “Sponsor”). Financing The registration statement for the Company’s IPO became effective on April 6, 2022. On April 11, 2022, the Company consummated the IPO of 8,250,000units (including over-allotment of 750,000units) (“Public Units”). Each Public Unit consists of oneClass A ordinary share, $ 0.0001par value per share (such shares included in the Public Units, the “Public Shares”), and oneredeemable warrant (the “Public Warrants”), each whole Public Warrant entitling the holder thereof to purchase onePublic Share at an exercise price of $ 11.50per share. The Public Units were sold at a price of $ 10.00per Public Unit, generating gross proceeds of $